Core Insights - The annual stress test results indicate that all 22 tested banks passed, demonstrating strong capital levels under a less severe scenario compared to the previous year [1][7] - The Federal Reserve's vice chair for supervision confirmed that large banks are well-capitalized and resilient to severe economic outcomes [1] Group 1: Stress Test Overview - The Federal Reserve conducts annual stress tests to assess the largest U.S. banks' ability to withstand significant economic downturns, determining minimum capital requirements and influencing share repurchases and dividends [2] - The stress test evaluates banks' financial resilience by estimating losses, revenues, expenses, and resulting capital levels under hypothetical economic conditions, including baseline and severely adverse scenarios [3] Group 2: Details of This Year's Test - This year's severely adverse scenario included a smaller increase in the unemployment rate and a less severe decline in house prices compared to the previous year [4] - All 22 banks maintained capital levels above the required threshold in a scenario where GDP contracts by 8%, commercial real estate prices decline by 30%, house prices drop by 33%, and the unemployment rate rises to 10% [5] Group 3: Capital Ratios and Loss Projections - The minimum common equity tier 1 capital ratio required to pass the test is 4.5%, while the banks collectively had a ratio of 11.6% during the stress scenario, absorbing projected hypothetical losses exceeding $550 billion [6] - Projected losses included approximately $158 billion in credit card losses, $124 billion from commercial and industrial loans, and $52 billion from commercial real estate [6] Group 4: Regulatory Implications - With all banks passing the stress test, they are positioned to issue dividends and buy back shares, returning capital to investors [7] - The Federal Reserve proposed easing capital rules, potentially freeing up $213 billion for bank subsidiaries and enhancing profitability [7][11] Group 5: Proposed Regulatory Changes - The Fed's proposal aims to reduce capital requirements for Global Systemically Important Banks (GSIBs) by 1.4% or $13 billion, and for depository institution subsidiaries by 27% or $213 billion [11] - The proposed changes would replace current enhanced Supplementary Leverage Ratio (SLR) buffers with a new structure based on each bank's GSIB surcharge, allowing banks more flexibility in managing low-risk assets [12]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - FIBRA Prologis is a leading owner and operator of Class-A logistics real estate in Mexico [4] - As of March 31, 2025, the company's portfolio includes 507 investment properties totaling 87.0 million square feet (8.1 million square meters) [4] - The portfolio consists of 345 logistics and manufacturing facilities across six industrial core markets in Mexico, comprising 65.5 million square feet (6.1 million square meters) of Gross Leasing Area (GLA) [4] Upcoming Events - FIBRA Prologis will host a webcast and conference call on July 29, 2025, at 9:00 a.m. Mexico Time to discuss second quarter results, current market conditions, and future outlook [1] - Access to the live broadcast can be obtained through various toll-free numbers and a live webcast available on the company's Investor Relations section [2] Telephonic Replay - A telephonic replay of the conference call will be available from July 29 to August 5, 2025, using specific conference codes for different regions [3]

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd. (TSX: “NPK”) ("Verde” or the “Company”) held its Annual General Meeting of shareholders (the “Meeting”) on Monday, June 30, 2025, at 300 Prof. Antônio Aleixo, Lourdes Belo Horizonte, Minas Gerais Brazil, and is pleased to announce that its shareholders approved all items put before them. The results were as follows: Item Voted UponVoting Results Votes ForVotes AgainstAdoption of the 2024 Audited Statement of Accounts10,835,601(98.971%)112,679 ...

Bollène (France), June 30, 2025 – 06 :00pm (CET)Press Releases Availabilityof the 2024 annual financial report Egide Group (Euronext Growth Paris™- ISIN: FR0000072373 - Ticker: ALGID), worldwide provider of hermetic packages and connectors and heat dissipation solutions for sensitive electronic components, announces that it has made available to the public and filed with the French Financial Markets Authority (AMF) its Annual Financial Report as of December 31, 2024. The 2024 Annual Financial Report can be ...

Key Takeaways Vistra has repurchased $5.2B in shares since 2021, with $1.5B more authorized through 2026. Buybacks are backed by strong free cash flow and align with Vistra's clean energy investments. VST shares are up 41.4% in six months, outperforming the Utility-Electric Power industry's 8% growth.Vistra Corp.’s (VST) aggressive share repurchase initiative is central to its long-term value creation strategy. Since November 2021, the company has repurchased shares worth $5.2 billion of its own shares th ...

Key Takeaways VRT expands liquid cooling for high-density AI data centers. iGenius win features NVIDIA-optimized prefab modules. Orders up 13%, backlog hits $7.9B in Q1 2025.Vertiv (VRT) is expanding liquid cooling solutions across its AI infrastructure portfolio to accelerate deployment and support large-scale data center growth. These advanced thermal systems, including heat rejection units and liquid distribution architecture, are being integrated into prefabricated modules, enabling faster rollout of ...

近期，香港稳定币的探索引起广泛关注。部分企业声称已经能够让个人或企业购买稳定币。对此，京东币链科技6月 30日发布《关于京东稳定币产品及业务合作不实信息的严正声明》，称近期关注到某些企业发布有关和京东币链展开合作 的信息，存在失实情况，误导了行业和公众舆论。请大家注意甄别，警惕"荐股"类骗局，避免财产损失。 刘鹏还提醒公众，目前京东稳定币尚未正式发行，并没有渠道可以购买京东稳定币。此类信息皆为误导诈骗信息。公 众可搜索"京东币链科技"获取京东稳定币的实时进展。 声明表示，目前京东币链科技并没有开始发行稳定币，也没有设立任何相关社区，目前所有获取京东稳定币的信息均 涉嫌欺诈。有关产品和企业业务合作信息，请以京东币链在官网发布的信息为准。对侵犯京东利益的不实信息，保留追究 其法律责任的权利。 记者注意到，京东创始人刘强东在近日的分享会上也谈到了稳定币，表示稳定币是京东6个创新项目之一，希望在全 球主要货币国家都申请稳定币牌照，通过稳定币牌照能够实现全球企业之间的汇兑，能够把全球的跨境支付成本降低 90%，效率提高到10秒钟之内。 京东币链科技CEO刘鹏近期透露，京东稳定币是一种基于公链并与港元（HKD）或美元（U ...

Financial Data and Key Metrics Changes - The company has sufficient cash to complete its trials, with an expected cash runway extending into 2028, indicating no immediate financial overhang [8] Business Line Data and Key Metrics Changes - The lead compound, ABTX009, is currently in Phase 2b of the LOTUS trial, with results expected in mid-2026 [7] - The company is targeting hidradenitis suppurativa (HS), a severe skin disease, with a significant unmet medical need [5][12] Market Data and Key Metrics Changes - The HS market is evolving, with new therapies emerging, but there remains a substantial unmet need for more effective treatments [11][12] - The market for HS is projected to grow significantly, with conservative estimates suggesting it could reach $10 billion by 2035 [42] Company Strategy and Development Direction - The company aims to transition rapidly into Phase 3 trials following the Phase 2 results, with a potential BLA filing anticipated around 2029 [34] - The strategy includes differentiating ABTX009 from competitors by focusing on its higher potency and longer half-life compared to existing therapies [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the mechanism of action of ABTX009, highlighting its potential to treat additional immune-mediated inflammatory diseases [8] - The management noted that dermatologists are increasingly looking for new therapies due to the limitations of current treatments, indicating a favorable environment for new entrants [35][38] Other Important Information - The trial design for ABTX009 is similar to that of other recent studies, with a focus on clinically relevant endpoints [27] - The company is studying a diverse patient demographic across the US, Canada, Australia, and Europe, which may help in achieving robust treatment effects [31] Q&A Session Summary Question: Can you discuss the current state of HS and the effectiveness of emerging therapies? - Management highlighted that HS is a severe disease with significant pain and disability, and there is a growing recognition of the need for better therapies [11] Question: What differentiates ABTX009 from other IL-1 strategies? - Management emphasized that targeting IL-1 beta specifically is advantageous, as it plays a pivotal role in chronic inflammation associated with HS [20][21] Question: What are the expectations for the Phase 2 trial data readout in 2026? - The study is powered to show a placebo-subtracted efficacy rate of 25-30%, with a robust treatment effect expected [28][30] Question: How does the company plan to carve out a commercial niche in the HS market? - Management believes that with a differentiated side effect profile and superior efficacy, ABTX009 can capture a significant share of the market [39][42] Question: What are the potential additional indications for IL-1 beta? - Management mentioned several potential indications, including Crohn's disease and rheumatoid arthritis, highlighting the broad applicability of IL-1 beta targeting [43][44]

Core Insights - EUROAPI has signed a share purchase agreement for the sale of 100% of EUROAPI UK Ltd, which operates the Haverhill manufacturing site, to Particle Dynamics [1][2] - The divestment is part of EUROAPI's strategy to optimize its industrial footprint and advance its FOCUS-27 transformation plan, enhancing efficiency and focus on its strategic network [2] - The Haverhill site generated approximately 35 million euros in net sales in 2024, with nearly 80% attributed to Sanofi [2] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, offering around 200 products and developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company operates six manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]